Press release
Nadrich & Cohen, LLP Now Investigating Pradaxa Side Effects Claims in All 50 States
National law firm Nadrich & Cohen, LLP is now offering free initial case evaluations to patients in all 50 states who suffered side effects caused by Pradaxa.Los Angeles, CA, January 20, 2012 – Prominent national law firm Nadrich & Cohen, LLP is pleased to announce that the firm is now representing individuals who believe they were injured by Pradaxa, a blood thinner used to treat patients with a heart rhythm problem known as atrial fibrillation. A recent research study has linked Pradaxa (dabigatran) to an increased risk of heart attack, angina and other serious complications in certain patients.
Pradaxa is manufactured by German pharmaceutical company Boehringer Ingelheim GmbH (BING) and was first approved for use as an anticoagulant by the FDA in 2010. In addition to treating patients with atrial fibrillation, the drug is also used to prevent blood clots in patients who’ve undergone joint replacement surgery.
On January 9, a paper published in the Archives of Internal Medicine suggested that patients who take Pradaxa are as much as 33% percent more likely to experience a heart attack or angina compared with patients who used another type of blood thinning agent. Researchers pooled data from seven different research studies involving 30,514 patients who were given dabigatran, warfarin, enoxaparin or a placebo.
In addition to the potential risk of heart attack associated with Pradaxa, the drug has also been linked to other serious side effects, including gastrointestinal bleeding, cerebral and brain hemorrhaging, ulcers, bleeding in the kidneys and in some cases, death. According to a November 2011 Reuters article, Boehringer acknowledged that the drug had caused approximately 260 deaths worldwide.
If you or a loved one experienced a heart attack, internal bleeding or other complications after taking Pradaxa, you can complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced Pradaxa injury attorney to discuss your legal rights.
Nadrich & Cohen LLP offers confidential, no-cost consultations to Pradaxa users who believe they were harmed by the drug. Help is available by calling 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling Pradaxa side effects claims, Nadrich & Cohen, LLP investigates cases involving Accutane, Avandia, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Vaginal Mesh, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan.
The time you have to file an injury claim is limited, so it’s important to act as quickly as possible to protect your rights. Call 1-800-722-0765 today to speak with a qualified personal injury expert or visit www.personalinjurylawcal.com.
Nadrich & Cohen LLP is a national law firm specializing in representing individuals who have been injured by defective medical devices, harmful prescription drugs, faulty products, car accidents, motorcycle accidents and dog bites.
Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nadrich & Cohen, LLP Now Investigating Pradaxa Side Effects Claims in All 50 States here
News-ID: 207996 • Views: …
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation.
Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed…
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.
Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.…
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants.
Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems.
The two-day panel, which is expected…
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the…
More Releases for Pradaxa
Pradaxa Market
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Pradaxa Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
Pradaxa Market Size And Scope
The Pradaxa market has shown steady growth, primarily driven by the increasing prevalence of thromboembolic disorders such as atrial fibrillation and deep…
Pradaxa Market is Rising in Upcoming Years | 2024-2031
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Pradaxa Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in the…
European Anticoagulants Market Share 2021: Trends, Key Players, Industry Analysi …
European anticoagulants market is estimated to grow at a CAGR of 6.6% during the forecast period. A significant rise in the demand for NOACs has been reported in the region, which in turn, is accelerating the market growth. The use of novel oral anticoagulants (NOACs) is growing significantly in Europe as their advantages over older drugs including warfarin. NOACs have demonstrated tremendous safety and efficacy without the requirement of subsequent…
Dibigatran Market Technology, Recent Trends, Future Growth Analysis Forecasts 20 …
Dabigatran, also known as Pradaxa, is an anticoagulant that is used to treat and prevent blood clots as well as stroke in persons who have atrial fibrillation. It's used to avoid blood clots after hip or knee replacement, as well as in people who have had previous clots.
Request Sample Copy of Dibigatran Market Report: https://www.infinitybusinessinsights.com/request_sample.php?id=603638
Top Key Players Included in Dibigatran Market Report: Pfizer, Inc. (US), Bayer Healthcare AG (Germany), GlaxoSmithKline…
Global Anticoagulant Reversal Drugs Market was Valued at $822.5 Million in 2019 …
Anticoagulant reversal drugs are used when the anticoagulant drug needs to be reversed the side effect such as bleeding complications, an overdose of the anticoagulant drug, or unplanned surgery. Some of the commercialized anticoagulant reversal drugs include Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa.
Increasing regulatory approval for anticoagulant reversal drugs is the major driving factor for the market. For instance, The U.S. Food and Drug Administration…
Anticoagulants Market 2021 Business Opportunities and Future Growth Outlook - Ba …
“Global Anticoagulants Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024 Edition)”
The New report includes a detailed study of Global Anticoagulants Market. It is the result of a comprehensive research carried out keeping in mind the different parameters and trends dominating the global Pet Insurance Market.
Buy Report@:
https://www.marketinsightsreports.com/report/purchase/08262257639?mode=su?Mode=NC
Top Key Players in the Market:
Bayer Group, BMS/Pfizer, Boehringher Ingelheim, Daiichi Sankyo
Moreover, the report also assesses the key opportunities in the market…